Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse

Abstract

Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive markers to identify these patients who can stop imatinib without relapse. © 2014 Landes Bioscience.